Radioactive drug plus immunotherapy shows promise for rare skin cancer

NCT ID NCT05583708

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and lutetium Lu 177 dotatate (a radioactive drug that kills cancer cells)—in 18 adults with Merkel cell carcinoma. The goal is to see if the combination can shrink or control tumors. Both drugs are FDA-approved for other cancers, but their use together for Merkel cell cancer is experimental.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MERKEL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous neuroendocrine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Iowa Hospitals and Clinics

    RECRUITING

    Iowa City, Iowa, 52242, United States

    Contact Email: •••••@•••••

    Contact

  • University of Wisconsin Carbone Cancer Center

    RECRUITING

    Madison, Wisconsin, 53792, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Weill Cornell Medicine/NewYork-Presbyterian Hospital

    RECRUITING

    New York, New York, 10065, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact